Kiadis Pharma B.V. is focused on cell-based immunotherapy products for the treatment of life threatening diseases. Kiadis is focused on developing new cancer immunotherapeutics as well as novel adjunctive treatments for patients undergoing hematopoietic stem cell transplants.
The company’s lead product, K-NKoo2, is in a phase 2 study evaluating haplo-identical NK cells to prevent post-transplant relapse in AML and MDS.
Portfolio: MedSciences Capital II B.V.
Current stage: Acquired by Sanofi.